Drug intelligence / Profile preview

BFH772

Development stage: Phase 2
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Topical

Overview

BFH772 is a small molecule inhibitor developed as a potent and selective oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) kinase, with an IC50 value of 3 nM. It was investigated primarily for topical use in the treatment of erythematotelangiectatic rosacea and has also been studied in clinical trials for psoriasis and arthritis. The drug acts by inhibiting VEGFR2-mediated signaling pathways involved in angiogenesis and inflammation. Development was led by Novartis, but there are no approved indications or known brand names associated with this compound[1][2][5][7].

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on BFH772.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BFH772.

Explore the full profile